Compare · ICCC vs ORKA
ICCC vs ORKA
Side-by-side comparison of ImmuCell Corporation (ICCC) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $3.86B, about 44.0x ICCC ($87.8M).
- Over the past year, ICCC is up 46.6% and ORKA is up 409.4% - ORKA leads by 362.8 points.
- ORKA has hit the wire 11 times in the past 4 weeks while ICCC has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Oruka Therapeutics Inc.
- Price
- $9.86-0.70%
- $64.03+6.51%
- Market cap
- $87.8M
- $3.86B
- 1M return
- +9.92%
- +0.02%
- 1Y return
- +46.62%
- +409.39%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 11
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Latest ICCC
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
- Amendment: SEC Form 10-K/A filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
Latest ORKA
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth
- SEC Form 4 filed by Director Martin Christopher Nathan
- SEC Form 4 filed by Director Ball Kristine M
- SEC Form 4 filed by Director Fairmount Funds Management Llc
- Oruka Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Phase 2 Data could Transform these Biotechs from Clinical Promise to Market Validation
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
- Director Dambkowski Carl exercised 62,260 shares at a strike of $7.95 and sold $6,191,366 worth of shares (105,000 units at $58.97) as part of a pre-agreed trading plan, decreasing direct ownership by 37% to 73,743 units (SEC Form 4)